Selected article for: "antibody expression and cell line"

Author: Miyakawa, Kei; Matsunaga, Satoko; Yamaoka, Yutaro; Dairaku, Mina; Fukano, Kento; Kimura, Hirokazu; Chimuro, Tomoyuki; Nishitsuji, Hironori; Watashi, Koichi; Shimotohno, Kunitada; Wakita, Takaji; Ryo, Akihide
Title: Development of a cell-based assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide
  • Cord-id: qrt07zmz
  • Document date: 2018_5_4
  • ID: qrt07zmz
    Snippet: Sodium taurocholate cotransporting polypeptide (NTCP) is a major entry receptor of hepatitis B virus (HBV) and one of the most attractive targets for anti-HBV drugs. We developed a cell-mediated drug screening method to monitor NTCP expression on the cell surface by generating a HepG2 cell line with tetracycline-inducible expression of NTCP and a monoclonal antibody that specifically detects cell-surface NTCP. Using this system, we screened a small molecule library for compounds that protected a
    Document: Sodium taurocholate cotransporting polypeptide (NTCP) is a major entry receptor of hepatitis B virus (HBV) and one of the most attractive targets for anti-HBV drugs. We developed a cell-mediated drug screening method to monitor NTCP expression on the cell surface by generating a HepG2 cell line with tetracycline-inducible expression of NTCP and a monoclonal antibody that specifically detects cell-surface NTCP. Using this system, we screened a small molecule library for compounds that protected against HBV infection by targeting NTCP. We found that glabridin, a licorice-derived isoflavane, could suppress viral infection by inducing caveolar endocytosis of cell-surface NTCP with an IC(50) of ~40 μM. We also found that glabridin could attenuate the inhibitory effect of taurocholate on type I interferon signaling by depleting the level of cell-surface NTCP. These results demonstrate that our screening system could be a powerful tool for discovering drugs targeting HBV entry.

    Search related documents:
    Co phrase search for related documents
    • absence presence and additional effect: 1
    • absence presence and liver cirrhosis: 1, 2, 3, 4, 5
    • absence presence and long term treatment: 1, 2
    • absence presence and low molecular weight: 1, 2, 3
    • absence presence and luciferase reporter: 1, 2, 3, 4, 5
    • absence presence and luciferase reporter gene: 1, 2
    • addition time and liver cirrhosis: 1
    • addition time and long term culture: 1, 2
    • addition time and long term treatment: 1
    • addition time and low molecular weight: 1
    • addition time and luciferase reporter: 1
    • addition time and luciferase reporter gene: 1
    • additional effect and liver cirrhosis: 1
    • additional effect and luciferase system: 1
    • liver cirrhosis and long term treatment: 1, 2, 3
    • liver cirrhosis and luciferase reporter: 1, 2
    • liver cirrhosis and luciferase reporter gene: 1
    • loading buffer and luciferase reporter: 1
    • loading buffer and luciferase reporter gene: 1